Profile data is unavailable for this security.
About the company
Divi's Laboratories Limited is an India-based company, which is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl and Vigabatrin. In addition to generic business, the Company, through its custom synthesis business, supports pharma companies for their patented products business right from gram scale requirements for clinical trials to launch, as well as late life cycle management. The Company’s subsidiaries include Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG.
- Revenue in INR (TTM)74.93bn
- Net income in INR13.83bn
- Incorporated1990
- Employees16.95k
- LocationDivi's Laboratories Ltd1-72/23(P)/Divis/303, Divi Towers, Cyber Hills, Gachibowli,HYDERABAD 500032IndiaIND
- Phone+91 4 023786300
- Fax+91 4 023786460
- Websitehttps://www.divislabs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkem Laboratories Ltd | 126.34bn | 15.73bn | 652.38bn | 16.87k | 41.47 | -- | 34.91 | 5.16 | 131.58 | 131.58 | 1,056.65 | -- | -- | -- | -- | 7,488,804.00 | -- | 11.44 | -- | 17.01 | 59.75 | 58.84 | 12.46 | 13.31 | -- | 5.83 | -- | 30.96 | 9.08 | 12.52 | -40.19 | 9.30 | -19.38 | 13.97 |
| Aurobindo Pharma Ltd | 278.95bn | 27.70bn | 720.62bn | 15.69k | 26.03 | -- | 16.84 | 2.58 | 47.25 | 47.25 | 475.59 | -- | -- | -- | -- | 17,778,640.00 | -- | 9.84 | -- | 14.92 | 55.29 | 53.05 | 9.92 | 13.06 | -- | 23.89 | -- | 8.33 | 5.97 | 8.54 | -27.21 | -4.47 | 12.20 | 3.71 |
| Lupin Ltd | 200.11bn | 19.14bn | 744.08bn | 18.97k | 38.97 | 5.21 | 23.75 | 3.72 | 41.89 | 41.89 | 437.85 | 313.60 | 0.8524 | 1.41 | 4.36 | -- | 8.24 | 1.43 | 13.34 | 2.22 | 66.80 | 59.70 | 9.67 | 2.04 | 0.9991 | 8.64 | 0.1689 | 79.28 | 20.25 | 6.41 | 345.15 | 30.18 | -1.17 | 9.86 |
| Mankind Pharma Ltd | 103.35bn | 19.13bn | 841.33bn | 18.47k | 44.03 | 8.98 | 35.95 | 8.14 | 47.69 | 47.69 | 257.65 | 233.73 | -- | -- | -- | -- | -- | -- | -- | -- | 68.94 | -- | 18.79 | -- | 2.37 | 116.65 | 0.0212 | -- | 18.12 | -- | 49.23 | -- | -- | -- |
| Torrent Pharmaceuticals Ltd | 104.74bn | 15.03bn | 911.40bn | 13.57k | 60.59 | -- | 39.64 | 8.70 | 44.44 | 44.44 | 309.68 | -- | -- | -- | -- | 7,716,901.00 | -- | 6.70 | -- | 10.48 | 74.12 | 70.84 | 14.35 | 11.22 | -- | 6.32 | -- | 63.62 | 13.07 | 10.09 | 60.22 | 12.92 | -6.22 | 25.74 |
| Dr Reddy's Laboratories Ltd | 280.11bn | 55.78bn | 982.14bn | 24.83k | 17.63 | 3.48 | 13.94 | 3.51 | 334.61 | 334.61 | 1,680.33 | 1,696.70 | 0.7874 | 1.46 | 3.67 | -- | 15.68 | 11.37 | 21.05 | 16.02 | 70.69 | 66.52 | 19.91 | 14.63 | 1.92 | 41.27 | 0.0662 | 16.40 | 13.54 | 12.64 | 23.75 | 23.39 | 26.78 | 14.87 |
| Divi's Laboratories Ltd | 74.93bn | 13.83bn | 1.09tn | 16.95k | 78.93 | -- | 62.29 | 14.57 | 52.11 | 52.11 | 282.31 | -- | -- | -- | -- | 4,420,514.00 | -- | 18.50 | -- | 20.48 | 59.23 | 57.21 | 18.46 | 27.90 | -- | -- | -- | 31.31 | -13.31 | 14.70 | -38.41 | 15.76 | 11.55 | 24.57 |
| Zydus Lifesciences Ltd | 195.47bn | 38.37bn | 1.09tn | 23.03k | 28.65 | 5.51 | 23.78 | 5.59 | 37.91 | 38.14 | 193.16 | 197.11 | 0.7103 | 1.82 | 4.06 | -- | 13.92 | 9.05 | 19.29 | 14.01 | 68.14 | 62.16 | 19.60 | 14.33 | 1.51 | 22,696.00 | 0.0351 | 16.48 | 13.40 | 8.23 | 95.25 | 15.72 | -3.03 | -3.04 |
| Cipla Ltd | 257.74bn | 41.22bn | 1.20tn | 26.62k | 29.18 | 4.50 | 23.10 | 4.67 | 51.02 | 51.02 | 319.08 | 330.77 | 0.829 | 1.70 | 5.84 | -- | 13.37 | 10.09 | 16.16 | 12.40 | 65.78 | 59.69 | 16.12 | 12.66 | 2.71 | 58.30 | 0.0205 | 20.79 | 13.28 | 9.51 | 47.10 | 21.96 | 20.68 | 34.08 |
| Holder | Shares | % Held |
|---|---|---|
| SBI Funds Management Ltd.as of 30 Apr 2024 | 20.70m | 7.80% |
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2023 | 15.12m | 5.70% |
| The Vanguard Group, Inc.as of 09 May 2024 | 4.98m | 1.88% |
| Axis Asset Management Co. Ltd.as of 30 Apr 2024 | 4.52m | 1.70% |
| BlackRock Fund Advisorsas of 09 May 2024 | 3.34m | 1.26% |
| Norges Bank Investment Managementas of 30 Jun 2023 | 3.21m | 1.21% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 09 May 2024 | 2.16m | 0.81% |
| ICICI Prudential Asset Management Co. Ltd.as of 30 Apr 2024 | 2.12m | 0.80% |
| Wasatch Advisors, Inc.as of 31 Mar 2024 | 1.97m | 0.74% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 30 Apr 2024 | 1.79m | 0.67% |
